Maravai LifeSciences Holdings, Inc.
Symbol: MRVI
NASDAQ
9.86
USDMarkedspris i dag
-9.9573
P/E-forhold
-0.0063
PEG Ratio
2.48B
MRK Cap
- 0.00%
DIV Udbytte
Maravai LifeSciences Holdings, Inc. (MRVI) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2296.43 | 575 | 632.1 | 551.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 200.74 | 55.7 | 146.8 | 117.5 | ||||||
balance-sheet.row.inventory | 197.79 | 51.4 | 43.2 | 51.6 | ||||||
balance-sheet.row.other-current-assets | 73.01 | 17.8 | 25.8 | 19.7 | ||||||
balance-sheet.row.total-current-assets | 2767.97 | 699.9 | 847.9 | 740 | ||||||
balance-sheet.row.property-plant-equipment-net | 807.33 | 222.6 | 116.6 | 46.3 | ||||||
balance-sheet.row.goodwill | 1304.55 | 326 | 283.7 | 152.8 | ||||||
balance-sheet.row.intangible-assets | 897.69 | 221 | 216.7 | 117.6 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 2202.23 | 547 | 500.3 | 270.3 | ||||||
balance-sheet.row.long-term-investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.tax-assets | 1764.23 | 0 | 765.8 | 808.1 | ||||||
balance-sheet.row.other-non-current-assets | -113.5 | 9.3 | 40.3 | 52.9 | ||||||
balance-sheet.row.total-non-current-assets | 4696.11 | 787.5 | 1434.4 | 1178.2 | ||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-assets | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.account-payables | 35.04 | 10.7 | 6 | 8.2 | ||||||
balance-sheet.row.short-term-debt | 45.01 | 12.9 | 11.7 | 9.7 | ||||||
balance-sheet.row.tax-payables | 1 | 1 | 1 | 1.4 | ||||||
balance-sheet.row.long-term-debt-total | 2192.18 | 518.7 | 573.6 | 524.6 | ||||||
Deferred Revenue Non Current | 829.37 | 79.4 | 0 | 0 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 21.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 209.03 | 60.5 | 89.4 | 65.7 | ||||||
balance-sheet.row.total-non-current-liabilities | 3807.23 | 610.1 | 1266.9 | 1279.1 | ||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.capital-lease-obligations | 285.32 | 79.4 | 57.8 | 3.7 | ||||||
balance-sheet.row.total-liab | 4106.89 | 697.6 | 1377.1 | 1372.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 10.05 | 2.5 | 2.6 | 2.6 | ||||||
balance-sheet.row.retained-earnings | 1349.25 | 285.7 | 404.8 | 184.6 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.other-total-stockholders-equity | 507.98 | 128.5 | 137.9 | 128.4 | ||||||
balance-sheet.row.total-stockholders-equity | 1867.28 | 416.8 | 545.2 | 315.5 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.minority-interest | 1489.91 | 373.1 | 360 | 229.9 | ||||||
balance-sheet.row.total-equity | 3357.19 | 789.9 | 905.2 | 545.4 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 7464.08 | - | - | - | ||||||
Total Investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.total-debt | 2398.63 | 611 | 585.3 | 534.3 | ||||||
balance-sheet.row.net-debt | 102.2 | 36 | -46.9 | -17 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -147.04 | -119 | 490.7 | 469.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.53 | 48.8 | 38.1 | 24.8 | ||||||
cash-flows.row.deferred-income-tax | 756.46 | 754.9 | 42.3 | 46.9 | ||||||
cash-flows.row.stock-based-compensation | 40.66 | 34.6 | 18.7 | 10.5 | ||||||
cash-flows.row.change-in-working-capital | 29.5 | 97.8 | -45.1 | -176.6 | ||||||
cash-flows.row.account-receivables | 19.87 | 84.4 | -22.3 | -70.4 | ||||||
cash-flows.row.inventory | 4.85 | 0.6 | 9.5 | -21.6 | ||||||
cash-flows.row.account-payables | 1.84 | 5.3 | -1.6 | 0.7 | ||||||
cash-flows.row.other-working-capital | 17.96 | 7.5 | -30.7 | -85.3 | ||||||
cash-flows.row.other-non-cash-items | -686.93 | -690.9 | -8.7 | -6.2 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 32.68 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.acquisitions-net | 75.02 | -69.6 | -238.3 | 120 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | 6.42 | 12.9 | -12.2 | 0.5 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -56.82 | -122.3 | -267.6 | 105.7 | ||||||
cash-flows.row.debt-repayment | -5.92 | -5.8 | -13.9 | -6 | ||||||
cash-flows.row.common-stock-issued | -1.45 | 0 | 2.4 | 1.7 | ||||||
cash-flows.row.common-stock-repurchased | -0.35 | 0 | 0 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-financing-activites | -35.07 | -55.3 | -176 | -154.8 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -42.44 | -61.1 | -187.5 | -159 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 1.6 | 0 | -0.1 | ||||||
cash-flows.row.net-change-in-cash | -66.58 | -57.2 | 80.9 | 315.1 | ||||||
cash-flows.row.cash-at-end-of-period | 2296.43 | 575 | 632.1 | 551.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 2363.02 | 632.1 | 551.3 | 236.2 | ||||||
cash-flows.row.operating-cash-flow | 32.68 | 126.2 | 536 | 368.6 | ||||||
cash-flows.row.capital-expenditure | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.free-cash-flow | -30.67 | 60.7 | 518.9 | 353.7 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 274.1 | 288.9 | 883 | 799.2 | ||||||
income-statement-row.row.cost-of-revenue | 154 | 151.3 | 169 | 140.6 | ||||||
income-statement-row.row.gross-profit | 120.1 | 137.6 | 714 | 658.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 18.17 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.other-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.operating-expenses | 166.92 | 141.8 | 147.6 | 115.3 | ||||||
income-statement-row.row.cost-and-expenses | 320.92 | 293.1 | 316.6 | 255.8 | ||||||
income-statement-row.row.interest-income | 28.89 | 27.7 | 2.3 | 30.3 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.total-operating-expenses | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.depreciation-and-amortization | 25.72 | 48.8 | -5.8 | -11 | ||||||
income-statement-row.row.ebitda-caps | -19.96 | - | - | - | ||||||
income-statement-row.row.operating-income | -45.68 | -4.2 | 574.2 | 554.6 | ||||||
income-statement-row.row.income-before-tax | 599.85 | 617.7 | 551.5 | 530.8 | ||||||
income-statement-row.row.income-tax-expense | 759.56 | 756.1 | 60.8 | 61.5 | ||||||
income-statement-row.row.net-income | -131.04 | -119 | 490.7 | 469.3 |
Ofte stillede spørgsmål
Hvad er Maravai LifeSciences Holdings, Inc. (MRVI) samlede aktiver?
Maravai LifeSciences Holdings, Inc. (MRVI) samlede aktiver er 1487450000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 138320000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.438.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -0.232.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -0.478.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -0.167.
Hvad er Maravai LifeSciences Holdings, Inc. (MRVI) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -119029000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 610967000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 141799000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 561691000.000.